Phase 1/2 study of HFB30132A
Latest Information Update: 08 Dec 2020
At a glance
- Drugs Enuzovimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors HiFiBiO
- 08 Dec 2020 New trial record
- 23 Nov 2020 According to a HiFiBiO Therapeutics media release, IND for HFB30132A submitted to the Ministry of Health of the Russian Federation and clinical sites selected for a Phase I/II, randomized, double-blind, placebo-controlled, two-stage, multicenter study